JP6038051B2 - 網膜の疾患を治療するための方法 - Google Patents
網膜の疾患を治療するための方法 Download PDFInfo
- Publication number
- JP6038051B2 JP6038051B2 JP2013554644A JP2013554644A JP6038051B2 JP 6038051 B2 JP6038051 B2 JP 6038051B2 JP 2013554644 A JP2013554644 A JP 2013554644A JP 2013554644 A JP2013554644 A JP 2013554644A JP 6038051 B2 JP6038051 B2 JP 6038051B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- hydrogen
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000017442 Retinal disease Diseases 0.000 title claims description 16
- 238000000034 method Methods 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims description 82
- 125000000217 alkyl group Chemical group 0.000 claims description 61
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000005842 heteroatom Chemical group 0.000 claims description 23
- 208000002780 macular degeneration Diseases 0.000 claims description 23
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 22
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- 125000001188 haloalkyl group Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 210000001525 retina Anatomy 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 206010038848 Retinal detachment Diseases 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 230000004264 retinal detachment Effects 0.000 claims description 9
- 239000011593 sulfur Substances 0.000 claims description 9
- 230000002207 retinal effect Effects 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 4
- 208000027073 Stargardt disease Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 239000000790 retinal pigment Substances 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000016624 Retinal neoplasm Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000032578 Inherited retinal disease Diseases 0.000 claims 1
- 208000032430 Retinal dystrophy Diseases 0.000 claims 1
- 201000006321 fundus dystrophy Diseases 0.000 claims 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- -1 1-methyl-4-pyridazin-4-yl-1H-pyrazol-3-yl Chemical group 0.000 description 33
- 208000035719 Maculopathy Diseases 0.000 description 14
- 201000004569 Blindness Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- AZEXWHKOMMASPA-UHFFFAOYSA-N 2-{[4-(1-methyl-4-pyridin-4-yl-1h-pyrazol-3-yl)phenoxy]methyl}quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 AZEXWHKOMMASPA-UHFFFAOYSA-N 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000004393 visual impairment Effects 0.000 description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 210000000608 photoreceptor cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000003161 choroid Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 4
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 4
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 3
- 206010025421 Macule Diseases 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 150000001447 alkali salts Chemical class 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 108091008695 photoreceptors Proteins 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000003890 succinate salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000001351 Epiretinal Membrane Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 2
- 101000687592 Homo sapiens Retinol dehydrogenase 8 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000031471 Macular fibrosis Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000002367 Retinal Perforations Diseases 0.000 description 2
- 201000007737 Retinal degeneration Diseases 0.000 description 2
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 102100024844 Retinol dehydrogenase 8 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 201000007917 background diabetic retinopathy Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 108091005996 glycated proteins Proteins 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000018769 loss of vision Diseases 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RUHAIMFLJXRIOR-LJQANCHMSA-N (2r)-1-[4-pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-1-yl]propan-2-ol Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C[C@H](O)C)C=C1C1=CC=NC=C1 RUHAIMFLJXRIOR-LJQANCHMSA-N 0.000 description 1
- RUHAIMFLJXRIOR-IBGZPJMESA-N (2s)-1-[4-pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-1-yl]propan-2-ol Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C[C@@H](O)C)C=C1C1=CC=NC=C1 RUHAIMFLJXRIOR-IBGZPJMESA-N 0.000 description 1
- DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 1
- 125000005859 (C1-C6)alkanoyloxymethyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- RUHAIMFLJXRIOR-UHFFFAOYSA-N 1-[4-pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-1-yl]propan-2-ol Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(O)C)C=C1C1=CC=NC=C1 RUHAIMFLJXRIOR-UHFFFAOYSA-N 0.000 description 1
- OMRQGOHJLIKRNJ-UHFFFAOYSA-N 1-[4-pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-1-yl]propan-2-ol Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N(CC(O)C)N=CC=1C1=CC=NC=C1 OMRQGOHJLIKRNJ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- JYFZUNQQRAJGHS-UHFFFAOYSA-N 2-[1-[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]ethyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1C(C)OC(C=C1)=CC=C1C1=NN(C)C=C1C1=CC=NC=C1 JYFZUNQQRAJGHS-UHFFFAOYSA-N 0.000 description 1
- QEDXQTGIBNYPTN-UHFFFAOYSA-N 2-[2-[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenyl]ethyl]quinoline Chemical compound C=1C=C(CCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 QEDXQTGIBNYPTN-UHFFFAOYSA-N 0.000 description 1
- FTOVUYIQDPEFAM-UHFFFAOYSA-N 2-[2-[4-(4-pyridin-4-yl-1h-pyrazol-5-yl)phenyl]ethyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1CCC(C=C1)=CC=C1C=1NN=CC=1C1=CC=NC=C1 FTOVUYIQDPEFAM-UHFFFAOYSA-N 0.000 description 1
- UJAGLBQVYJPDDQ-UHFFFAOYSA-N 2-[[2,3-difluoro-4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C(F)=C(F)C=1C1=NN(C)C=C1C1=CC=NC=C1 UJAGLBQVYJPDDQ-UHFFFAOYSA-N 0.000 description 1
- JUCIQNCMRHCEFW-UHFFFAOYSA-N 2-[[2-chloro-4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C(Cl)=CC=1C1=NN(C)C=C1C1=CC=NC=C1 JUCIQNCMRHCEFW-UHFFFAOYSA-N 0.000 description 1
- SODQNGJPEKNZBT-UHFFFAOYSA-N 2-[[2-chloro-4-(4-pyridin-4-yl-1h-pyrazol-5-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C(Cl)=CC=1C1=NNC=C1C1=CC=NC=C1 SODQNGJPEKNZBT-UHFFFAOYSA-N 0.000 description 1
- OIUFHLZLDYGIKF-UHFFFAOYSA-N 2-[[2-fluoro-4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C(F)=CC=1C1=NN(C)C=C1C1=CC=NC=C1 OIUFHLZLDYGIKF-UHFFFAOYSA-N 0.000 description 1
- YOABOEUHOSBBNP-UHFFFAOYSA-N 2-[[2-fluoro-4-(4-pyridin-4-yl-1h-pyrazol-5-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C(F)=CC=1C1=NNC=C1C1=CC=NC=C1 YOABOEUHOSBBNP-UHFFFAOYSA-N 0.000 description 1
- HFOVYIVZZFUCME-UHFFFAOYSA-N 2-[[3-fluoro-4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=C(F)C=1C1=NN(C)C=C1C1=CC=NC=C1 HFOVYIVZZFUCME-UHFFFAOYSA-N 0.000 description 1
- VXZDAYNHUOIVSC-UHFFFAOYSA-N 2-[[3-fluoro-4-(4-pyridin-4-yl-1h-pyrazol-5-yl)phenoxy]methyl]quinoline Chemical compound FC1=CC(OCC=2N=C3C=CC=CC3=CC=2)=CC=C1C1=NNC=C1C1=CC=NC=C1 VXZDAYNHUOIVSC-UHFFFAOYSA-N 0.000 description 1
- DXDMXTCWTGFOSL-UHFFFAOYSA-N 2-[[3-fluoro-4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound FC1=CC(OCC=2N=C3C=CC=CC3=CC=2)=CC=C1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 DXDMXTCWTGFOSL-UHFFFAOYSA-N 0.000 description 1
- QVAGVWYSZVEZTK-UHFFFAOYSA-N 2-[[3-fluoro-4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoxaline Chemical compound FC1=CC(OCC=2N=C3C=CC=CC3=NC=2)=CC=C1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 QVAGVWYSZVEZTK-UHFFFAOYSA-N 0.000 description 1
- XEDXYELVMICFBM-UHFFFAOYSA-N 2-[[4-(1,5-dimethyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C)C(C)=C1C1=CC=NC=C1 XEDXYELVMICFBM-UHFFFAOYSA-N 0.000 description 1
- MSCSERRKBGIMGH-UHFFFAOYSA-N 2-[[4-(1-ethyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC)C=C1C1=CC=NC=C1 MSCSERRKBGIMGH-UHFFFAOYSA-N 0.000 description 1
- PFJPPFUSUYKHEM-UHFFFAOYSA-N 2-[[4-(1-methyl-3-pyridin-4-ylpyrazol-4-yl)phenoxy]methyl]quinoline;2-[[4-(1-methyl-5-pyridin-4-ylpyrazol-4-yl)phenoxy]methyl]quinoline Chemical compound N=1N(C)C=C(C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)C=1C1=CC=NC=C1.CN1N=CC(C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)=C1C1=CC=NC=C1 PFJPPFUSUYKHEM-UHFFFAOYSA-N 0.000 description 1
- CZKBZJWEUBXTOX-UHFFFAOYSA-N 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]-1,8-naphthyridine Chemical compound C=1C=C(OCC=2N=C3N=CC=CC3=CC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 CZKBZJWEUBXTOX-UHFFFAOYSA-N 0.000 description 1
- ZEZDMKUSVITBJD-UHFFFAOYSA-N 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C=1C=C(OCC=2N=C3C=CC=CN3C(=O)C=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 ZEZDMKUSVITBJD-UHFFFAOYSA-N 0.000 description 1
- MQRWYRGIPCMEGU-UHFFFAOYSA-N 2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinazoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CN=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 MQRWYRGIPCMEGU-UHFFFAOYSA-N 0.000 description 1
- YEYYFESVOAQOMX-UHFFFAOYSA-N 2-[[4-(1-pyridin-4-ylimidazol-2-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C1=NC=CN1C1=CC=NC=C1 YEYYFESVOAQOMX-UHFFFAOYSA-N 0.000 description 1
- ZWPKCVMUCBJUQA-UHFFFAOYSA-N 2-[[4-(2,5-dimethyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound CC1=NN(C)C(C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)=C1C1=CC=NC=C1 ZWPKCVMUCBJUQA-UHFFFAOYSA-N 0.000 description 1
- UFBIOSDYTOETCT-UHFFFAOYSA-N 2-[[4-(2-ethyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N(CC)N=CC=1C1=CC=NC=C1 UFBIOSDYTOETCT-UHFFFAOYSA-N 0.000 description 1
- XLSBGYBUVUYTKT-UHFFFAOYSA-N 2-[[4-(2-ethyl-5-pyridin-4-ylimidazol-1-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1N1C(CC)=NC=C1C1=CC=NC=C1 XLSBGYBUVUYTKT-UHFFFAOYSA-N 0.000 description 1
- PRWFSBVVFNTTJQ-UHFFFAOYSA-N 2-[[4-(2-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N(C)N=CC=1C1=CC=NC=C1 PRWFSBVVFNTTJQ-UHFFFAOYSA-N 0.000 description 1
- DNLWHMOZXQHBRR-UHFFFAOYSA-N 2-[[4-(2-methyl-5-pyridin-4-ylimidazol-1-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1N1C(C)=NC=C1C1=CC=NC=C1 DNLWHMOZXQHBRR-UHFFFAOYSA-N 0.000 description 1
- GIFAHWUNLKIYPK-UHFFFAOYSA-N 2-[[4-(2-methyl-5-pyridin-4-ylpyrimidin-4-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NC(C)=NC=C1C1=CC=NC=C1 GIFAHWUNLKIYPK-UHFFFAOYSA-N 0.000 description 1
- LXPOXZQIXLTFOY-UHFFFAOYSA-N 2-[[4-(2-methyl-5-pyridin-4-yltriazol-4-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C)N=C1C1=CC=NC=C1 LXPOXZQIXLTFOY-UHFFFAOYSA-N 0.000 description 1
- HGYNUHZFZQPWJX-UHFFFAOYSA-N 2-[[4-(2-methyl-6-pyridin-4-yl-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N2N=C(C)N=C2N=CC=1C1=CC=NC=C1 HGYNUHZFZQPWJX-UHFFFAOYSA-N 0.000 description 1
- OJSGMQVIVWBQLU-UHFFFAOYSA-N 2-[[4-(2-methyl-6-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N2N=C(C)C=C2N=CC=1C1=CC=NC=C1 OJSGMQVIVWBQLU-UHFFFAOYSA-N 0.000 description 1
- JMZRPMAVNSJTHX-UHFFFAOYSA-N 2-[[4-(2-propan-2-yl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N(C(C)C)N=CC=1C1=CC=NC=C1 JMZRPMAVNSJTHX-UHFFFAOYSA-N 0.000 description 1
- UIAMWGXJCFHIFQ-UHFFFAOYSA-N 2-[[4-(2-pyridin-4-yl-1,2,4-triazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C1=NC=NN1C1=CC=NC=C1 UIAMWGXJCFHIFQ-UHFFFAOYSA-N 0.000 description 1
- GFWUTXCUGOCRCU-UHFFFAOYSA-N 2-[[4-(2-pyridin-4-ylimidazol-1-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1N1C=CN=C1C1=CC=NC=C1 GFWUTXCUGOCRCU-UHFFFAOYSA-N 0.000 description 1
- FGZGUDDNJZWDEG-UHFFFAOYSA-N 2-[[4-(2-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C1=CC=NN1C1=CC=NC=C1 FGZGUDDNJZWDEG-UHFFFAOYSA-N 0.000 description 1
- QXUMUFUJVNUCLH-UHFFFAOYSA-N 2-[[4-(3-methyl-5-pyridin-4-yl-1,2,4-triazol-1-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1N1N=C(C)N=C1C1=CC=NC=C1 QXUMUFUJVNUCLH-UHFFFAOYSA-N 0.000 description 1
- ZCCNSFBJULJRFS-UHFFFAOYSA-N 2-[[4-(3-methyl-5-pyridin-4-yl-1,2,4-triazol-4-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1N1C(C)=NN=C1C1=CC=NC=C1 ZCCNSFBJULJRFS-UHFFFAOYSA-N 0.000 description 1
- AVUNUUGSMGKIPX-UHFFFAOYSA-N 2-[[4-(3-methyl-5-pyridin-4-ylpyrazol-1-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1N1N=C(C)C=C1C1=CC=NC=C1 AVUNUUGSMGKIPX-UHFFFAOYSA-N 0.000 description 1
- DVBMYTDVYSCDOG-UHFFFAOYSA-N 2-[[4-(3-methyl-5-pyridin-4-yltriazol-4-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N(C)N=NC=1C1=CC=NC=C1 DVBMYTDVYSCDOG-UHFFFAOYSA-N 0.000 description 1
- NBPVYBUFEQJIJU-UHFFFAOYSA-N 2-[[4-(4-pyridin-4-yl-1,2,4-triazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C1=NN=CN1C1=CC=NC=C1 NBPVYBUFEQJIJU-UHFFFAOYSA-N 0.000 description 1
- GFWCZCDOQVGMGE-UHFFFAOYSA-N 2-[[4-(5-methyl-2-pyridin-4-yl-1,2,4-triazol-3-yl)phenoxy]methyl]quinoline Chemical compound N1=C(C)N=C(C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)N1C1=CC=NC=C1 GFWCZCDOQVGMGE-UHFFFAOYSA-N 0.000 description 1
- ITJWXVOIUJXZHN-UHFFFAOYSA-N 2-[[4-(5-methyl-4-pyridin-4-yl-1h-pyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound CC1=NNC(C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)=C1C1=CC=NC=C1 ITJWXVOIUJXZHN-UHFFFAOYSA-N 0.000 description 1
- HMRVDKWASFSAKY-UHFFFAOYSA-N 2-[[4-(5-pyridin-4-yl-1,2,4-triazol-1-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1N1N=CN=C1C1=CC=NC=C1 HMRVDKWASFSAKY-UHFFFAOYSA-N 0.000 description 1
- VMXQQYQWYMJOIU-UHFFFAOYSA-N 2-[[4-(5-pyridin-4-yl-1h-pyrazol-4-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C=1C=NNC=1C1=CC=NC=C1 VMXQQYQWYMJOIU-UHFFFAOYSA-N 0.000 description 1
- AYKRTUWDZRNPRJ-UHFFFAOYSA-N 2-[[4-(5-pyridin-4-yl-2h-triazol-4-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C=1N=NNC=1C1=CC=NC=C1 AYKRTUWDZRNPRJ-UHFFFAOYSA-N 0.000 description 1
- YNRUGBMEUDBFKY-UHFFFAOYSA-N 2-[[4-(5-pyridin-4-ylimidazol-1-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1N1C=NC=C1C1=CC=NC=C1 YNRUGBMEUDBFKY-UHFFFAOYSA-N 0.000 description 1
- UEQMEJZSZAQCLM-UHFFFAOYSA-N 2-[[4-(5-pyridin-4-ylpyrazol-1-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1N1N=CC=C1C1=CC=NC=C1 UEQMEJZSZAQCLM-UHFFFAOYSA-N 0.000 description 1
- TZJPAPLAKPUOHH-UHFFFAOYSA-N 2-[[4-(5-pyridin-4-ylpyrimidin-4-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C1=NC=NC=C1C1=CC=NC=C1 TZJPAPLAKPUOHH-UHFFFAOYSA-N 0.000 description 1
- VVDGQEIGTLUYLR-UHFFFAOYSA-N 2-[[4-[1-(2-methylpropyl)-4-pyridin-4-ylpyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(C)C)C=C1C1=CC=NC=C1 VVDGQEIGTLUYLR-UHFFFAOYSA-N 0.000 description 1
- KBMUODSISGYDRZ-UHFFFAOYSA-N 2-[[4-[1-methyl-4-(2-methylpyridin-4-yl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C1=NC(C)=CC(C=2C(=NN(C)C=2)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)=C1 KBMUODSISGYDRZ-UHFFFAOYSA-N 0.000 description 1
- UXIXDURNQUVQSK-UHFFFAOYSA-N 2-[[4-[4-(2-chloropyridin-4-yl)-1-methylpyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC(Cl)=C1 UXIXDURNQUVQSK-UHFFFAOYSA-N 0.000 description 1
- CBTRSTAZMYXZQO-UHFFFAOYSA-N 2-[[4-[4-(2-chloropyridin-4-yl)-1h-pyrazol-5-yl]phenoxy]methyl]quinoline Chemical compound C1=NC(Cl)=CC(C=2C(=NNC=2)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)=C1 CBTRSTAZMYXZQO-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- JYHUJIBPGPHSOL-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoxaline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=NC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 JYHUJIBPGPHSOL-UHFFFAOYSA-N 0.000 description 1
- KOQAWTNMUMMWMO-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-2-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N(CC(F)(F)F)N=CC=1C1=CC=NC=C1 KOQAWTNMUMMWMO-UHFFFAOYSA-N 0.000 description 1
- XNNBTOQDOBHMPE-UHFFFAOYSA-N 2-methyl-1-[4-pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-1-yl]propan-2-ol Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(C)(O)C)C=C1C1=CC=NC=C1 XNNBTOQDOBHMPE-UHFFFAOYSA-N 0.000 description 1
- ZPKWTDOMHZQTDO-UHFFFAOYSA-N 2-methyl-1-[4-pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-1-yl]propan-2-ol Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N(CC(C)(O)C)N=CC=1C1=CC=NC=C1 ZPKWTDOMHZQTDO-UHFFFAOYSA-N 0.000 description 1
- MRHHLZOOXRHUHO-UHFFFAOYSA-N 2-methyl-5-pyridin-4-yl-4-[4-(quinolin-2-ylmethoxy)phenyl]-1,3-oxazole Chemical compound O1C(C)=NC(C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)=C1C1=CC=NC=C1 MRHHLZOOXRHUHO-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VRWJZGHUCOFGPZ-UHFFFAOYSA-N 2-{[4-(4-pyridin-4-yl-1h-pyrazol-3-yl)phenoxy]methyl}quinoline Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C1=NNC=C1C1=CC=NC=C1 VRWJZGHUCOFGPZ-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- RPYVFQPJTQCNIS-UHFFFAOYSA-N 3-methyl-5-[2-methyl-4-[4-(quinolin-2-ylmethoxy)phenyl]pyrimidin-5-yl]-1,2-oxazole Chemical compound O1N=C(C)C=C1C1=CN=C(C)N=C1C(C=C1)=CC=C1OCC1=CC=C(C=CC=C2)C2=N1 RPYVFQPJTQCNIS-UHFFFAOYSA-N 0.000 description 1
- SZCMPLDFCXLUHF-UHFFFAOYSA-N 4-(1h-pyrazol-4-yl)pyridazine Chemical compound C1=NNC=C1C1=CC=NN=C1 SZCMPLDFCXLUHF-UHFFFAOYSA-N 0.000 description 1
- WWQNFLWIICZHER-UHFFFAOYSA-N 4-chloro-2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=C(Cl)C=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 WWQNFLWIICZHER-UHFFFAOYSA-N 0.000 description 1
- GNDVGAFSWHFOOB-UHFFFAOYSA-N 4-pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)phenyl]-1,2-oxazole Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C=1ON=CC=1C1=CC=NC=C1 GNDVGAFSWHFOOB-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZWKPLQXNVSBVBS-UHFFFAOYSA-N 5-pyridin-4-yl-4-[4-(quinolin-2-ylmethoxy)phenyl]-1,3-oxazole Chemical compound C=1C=C2C=CC=CC2=NC=1COC(C=C1)=CC=C1C=1N=COC=1C1=CC=NC=C1 ZWKPLQXNVSBVBS-UHFFFAOYSA-N 0.000 description 1
- PKAOXXKFOIHDFF-UHFFFAOYSA-N 6-fluoro-2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline;hydron;chloride Chemical compound Cl.C=1C=C(OCC=2N=C3C=CC(F)=CC3=CC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 PKAOXXKFOIHDFF-UHFFFAOYSA-N 0.000 description 1
- IMQQGLRJBTZNFV-UHFFFAOYSA-N 7-chloro-2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline;hydron;2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoxaline;chloride Chemical compound Cl.C=1C=C(OCC=2N=C3C=CC=CC3=NC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1.C=1C=C(OCC=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 IMQQGLRJBTZNFV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ARNYNONKOHEEHV-UHFFFAOYSA-N 8-methoxy-2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenoxy]methyl]quinoline Chemical compound N1=C2C(OC)=CC=CC2=CC=C1COC(C=C1)=CC=C1C1=NN(C)C=C1C1=CC=NC=C1 ARNYNONKOHEEHV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102100022794 Bestrophin-1 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 208000034247 Pattern dystrophy Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000034461 Progressive cone dystrophy Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010038821 Retinal anomaly congenital Diseases 0.000 description 1
- 208000032400 Retinal pigmentation Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000034777 Vitreous degeneration Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- JACFYDNXVMGHFT-UHFFFAOYSA-N butanedioic acid;2-[[4-(1-methyl-4-pyridin-4-ylpyrazol-3-yl)phenyl]methoxy]quinoline Chemical compound OC(=O)CCC(O)=O.OC(=O)CCC(O)=O.C=1C=C(COC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(C)C=C1C1=CC=NC=C1 JACFYDNXVMGHFT-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- JUQJCAMVXDQFCM-UHFFFAOYSA-N chembl561056 Chemical compound O1N=C(C)C=C1C1=C(C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)NN=C1 JUQJCAMVXDQFCM-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 201000008615 cone dystrophy Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 229950010286 diolamine Drugs 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940048879 dl tartaric acid Drugs 0.000 description 1
- 229940110377 dl- arginine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- PQZLSDWIYHTJRV-UHFFFAOYSA-N n,n-dimethyl-2-[4-pyridin-4-yl-3-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-1-yl]ethanamine Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CCN(C)C)C=C1C1=CC=NC=C1 PQZLSDWIYHTJRV-UHFFFAOYSA-N 0.000 description 1
- MYNFJVRYHRCIKS-UHFFFAOYSA-N n,n-dimethyl-2-[4-pyridin-4-yl-5-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-1-yl]ethanamine Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C=1N(CCN(C)C)N=CC=1C1=CC=NC=C1 MYNFJVRYHRCIKS-UHFFFAOYSA-N 0.000 description 1
- GMFCXDHXBDXRLF-UHFFFAOYSA-N n,n-dimethyl-4-[1-methyl-3-[4-(quinolin-2-ylmethoxy)phenyl]pyrazol-4-yl]pyridin-2-amine Chemical compound C1=NC(N(C)C)=CC(C=2C(=NN(C)C=2)C=2C=CC(OCC=3N=C4C=CC=CC4=CC=3)=CC=2)=C1 GMFCXDHXBDXRLF-UHFFFAOYSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000024725 retina neoplasm Diseases 0.000 description 1
- 201000008933 retinal cancer Diseases 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000027653 severe early-childhood-onset retinal dystrophy Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001472 tertiary aliphatic amine group Chemical group 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 208000020939 vitelliform macular dystrophy 1 Diseases 0.000 description 1
- 201000011288 vitreous syneresis Diseases 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161444587P | 2011-02-18 | 2011-02-18 | |
| US201161444602P | 2011-02-18 | 2011-02-18 | |
| US61/444,587 | 2011-02-18 | ||
| US61/444,602 | 2011-02-18 | ||
| US201161482106P | 2011-05-03 | 2011-05-03 | |
| US201161482097P | 2011-05-03 | 2011-05-03 | |
| US61/482,106 | 2011-05-03 | ||
| US61/482,097 | 2011-05-03 | ||
| PCT/US2012/025685 WO2012112918A1 (en) | 2011-02-18 | 2012-02-17 | Methods for treating diseases of the retina |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506582A JP2014506582A (ja) | 2014-03-17 |
| JP2014506582A5 JP2014506582A5 (enExample) | 2015-04-16 |
| JP6038051B2 true JP6038051B2 (ja) | 2016-12-07 |
Family
ID=45787351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554644A Expired - Fee Related JP6038051B2 (ja) | 2011-02-18 | 2012-02-17 | 網膜の疾患を治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120214842A1 (enExample) |
| EP (1) | EP2675456A1 (enExample) |
| JP (1) | JP6038051B2 (enExample) |
| AR (1) | AR085285A1 (enExample) |
| AU (1) | AU2012219288A1 (enExample) |
| CA (1) | CA2827509A1 (enExample) |
| WO (1) | WO2012112918A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| FR3008618A1 (fr) * | 2013-07-19 | 2015-01-23 | Univ Paris Curie | Utilisation de composes pour restaurer la reponse a la lumiere des cellules de la retine |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| LT4175719T (lt) | 2020-07-02 | 2025-08-25 | Incyte Corporation | Tricikliniai karbamido dariniai kaip jak2 v617f inhibitoriai |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| UY40188A (es) | 2022-03-17 | 2023-10-13 | Incyte Corp | Compuestos de urea tricíclica como inhibidores de jak2 v617f |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006072828A2 (en) * | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| WO2007056210A2 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis |
| WO2007129183A2 (en) * | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| KR100816670B1 (ko) * | 2006-08-18 | 2008-03-27 | 국방과학연구소 | 망막 손상 치료 및 망막 보호하기 위한 메틸렌블루의 용도 |
| KR20120043775A (ko) * | 2006-12-21 | 2012-05-04 | 화이자 프로덕츠 인크. | 2-((4-(1-메틸-4-(피리딘-4-일)-1ｈ-피라졸-3-일)페녹시)메틸)퀴놀린의 숙시네이트 염 |
| US8349830B2 (en) * | 2009-10-30 | 2013-01-08 | Merck Sharp & Dohme | Aryl aminopyridine PDE10 inhibitors |
-
2012
- 2012-02-16 US US13/398,213 patent/US20120214842A1/en not_active Abandoned
- 2012-02-17 AR ARP120100553A patent/AR085285A1/es not_active Application Discontinuation
- 2012-02-17 EP EP12706981.3A patent/EP2675456A1/en not_active Withdrawn
- 2012-02-17 CA CA2827509A patent/CA2827509A1/en not_active Abandoned
- 2012-02-17 AU AU2012219288A patent/AU2012219288A1/en not_active Abandoned
- 2012-02-17 WO PCT/US2012/025685 patent/WO2012112918A1/en not_active Ceased
- 2012-02-17 JP JP2013554644A patent/JP6038051B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014506582A (ja) | 2014-03-17 |
| WO2012112918A1 (en) | 2012-08-23 |
| US20120214842A1 (en) | 2012-08-23 |
| EP2675456A1 (en) | 2013-12-25 |
| AU2012219288A1 (en) | 2013-09-05 |
| AR085285A1 (es) | 2013-09-18 |
| CA2827509A1 (en) | 2012-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6038051B2 (ja) | 網膜の疾患を治療するための方法 | |
| JP2022116191A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| TWI643619B (zh) | 一種用於預防或治療青光眼或高眼壓症、或降低眼壓之醫藥組合物及其用途 | |
| JP2020536896A (ja) | 炎症性障害の処置 | |
| WO2020259528A1 (zh) | 治疗特发性肺纤维化的方法 | |
| ZA200607491B (en) | Tetrahydrocarbazoles and derivatives | |
| US12290511B2 (en) | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | |
| JP2019521189A (ja) | ドライアイ、眼痛および炎症の処置のためのｔｒｐａ１アンタゴニスト | |
| CA2555172A1 (en) | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders | |
| KR20120096869A (ko) | 포스포이노시티드 ３-키나제 억제제 및 항당뇨병 화합물의 조합물 | |
| KR20200044873A (ko) | 안구 제약학적 조성물 | |
| CN106604730B (zh) | 角膜厚度调节剂 | |
| TWI516266B (zh) | 用於治療青光眼及高眼壓症之腺苷ａ１促效劑 | |
| TWI833535B (zh) | 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥 | |
| WO2019124489A1 (ja) | セペタプロストとｅｐ２アゴニストとの組み合わせ医薬 | |
| US20020160993A1 (en) | Method for treating glaucoma IC | |
| JP4578576B2 (ja) | ガチフロキサシン含有水性液剤 | |
| KR101891846B1 (ko) | (3-(1-(1h-이미다졸-4-일)에틸)-2-메틸페닐)메탄올을 포함하는 약제학적 조성물 | |
| TW201335149A (zh) | 治療視網膜疾病之方法 | |
| KR20150090045A (ko) | 피나플록사신 현탁 조성물 | |
| US20250170143A1 (en) | Methods of treating ocular fibrotic pathologies | |
| JP7588590B2 (ja) | 脳腫瘍および脳転移の治療剤としての２ｈ－インダゾール誘導体 | |
| EP3730143A1 (en) | Omidenepag combination | |
| HK40031074A (en) | Pharmaceutical preparation containing pyridyl aminoacetic acid compound | |
| HK40029828A (en) | Omidenepag combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150217 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150217 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160120 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160420 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160620 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160628 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161003 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161101 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6038051 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |